GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.
Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.
www.eosmedchem.com
1.
Semaglutide（910463-68-2) , HPLC 99%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock.
Name: Semaglutide
CAS#: 910463-68-2
Chemical Formula: C187H291N45O59
Exact Mass: 4111.1154
Molecular Weight: 4113.64
Elemental Analysis: C, 54.60; H, 7.13; N, 15.32; O, 22.95
Synonym: Semaglutide; NNC 0113-0217
IUPAC/Chemical Name: NNC 0113-0217; L-Histidyl-2-methylalanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(17-carboxy-1-oxoheptadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycine
InChi Key: NEPLHSBHWKHLHT-QLJXVRBESA-N
InChi Code: InChI=1S/C187H291N45O59/c1-18-104(10)152(178(281)208-107(13)157(260)216-132(86-113-89-200-118-50-40-39-49-116(113)118)168(271)218-128(82-101(4)5)169(272)228-150(102(6)7)176(279)215-120(53-44-74-199-185(194)195)160(263)201-91-141(243)209-119(52-43-73-198-184(192)193)159(262)204-94-149(256)257)230-170(273)130(83-110-45-33-31-34-46-110)219-165(268)125(64-69-147(252)253)214-164(267)121(51-41-42-72-197-183(287)187(291-80-79-289-76-71-189,138(240)98-290-78-77-288-75-70-188)137(239)65-60-126(181(284)285)211-140(242)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-144(246)247)212-156(259)106(12)206-155(258)105(11)207-163(266)124(61-66-139(191)241)210-142(244)92-202-161(264)122(62-67-145(248)249)213-166(269)127(81-100(2)3)217-167(270)129(85-112-56-58-115(238)59-57-112)220-173(276)134(95-233)223-175(278)136(97-235)224-177(280)151(103(8)9)229-172(275)133(88-148(254)255)221-174(277)135(96-234)225-180(283)154(109(15)237)231-171(274)131(84-111-47-35-32-36-48-111)222-179(282)153(108(14)236)227-143(245)93-203-162(265)123(63-68-146(250)251)226-182(286)186(16,17)232-158(261)117(190)87-114-90-196-99-205-114/h31-36,39-40,45-50,56-59,89-90,99-109,117,119-136,150-154,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-98,188-190H2,1-17H3,(H2,191,241)(H,196,205)(H,197,287)(H,201,263)(H,202,264)(H,203,265)(H,204,262)(H,206,258)(H,207,266)(H,208,281)(H,209,243)(H,210,244)(H,211,242)(H,212,259)(H,213,269)(H,214,267)(H,215,279)(H,216,260)(H,217,270)(H,218,271)(H,219,268)(H,220,276)(H,221,277)(H,222,282)(H,223,278)(H,224,280)(H,225,283)(H,226,286)(H,227,245)(H,228,272)(H,229,275)(H,230,273)(H,231,274)(H,232,261)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,254,255)(H,256,257)(H,284,285)(H4,192,193,198)(H4,194,195,199)/t104-,105-,106-,107-,108+,109+,117-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134+,135-,136-,150-,151-,152-,153-,154-,187?/m0/s1
SMILES Code: O=C(O)CNC([C@H](CCCNC(N)=N)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CCC(O)=O)NC([C@H](CCCCNC(C(C(COCCOCCN)=O)(C(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)OCCOCCN)=O)NC([C@H](C)NC([C@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC4=CC=C(O)C=C4)NC([C@@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC5=CC=CC=C5)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(C(C)(C)NC([C@H](CC6=CNC=N6)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
2
Semaglutide intermediates
Semaglutide intermediate, CAS# 72849-35-5, Octadecanedioic acid, 1-methyl ester ,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Semaglutide intermediate, CAS# 871-70-5, OCTADECANEDIOIC ACID ,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Semaglutide intermediate, CAS# 189625-51-2, OCTADECANEDIOIC ACID MONOBENZYL ESTER,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Semaglutide intermediate, CAS# 843666-40-0, Octadecanedioic acid mono-tert-butyl este,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
Semaglutide intermediate, CAS# 166108-71-0, Fmoc AEEA,HPLC 98%+, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.
REFERENCES
1: Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, Kiyosue A. Safety and efficacy of once-weekly semaglutide versus additional oral antidiabetic drugs, in Japanese subjects with inadequately controlled T2D: a randomised trial. Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13218. [Epub ahead of print] PubMed PMID: 29322610.
2: Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017 Dec;5(24):505. doi: 10.21037/atm.2017.11.10. PubMed PMID: 29299466; PubMed Central PMCID: PMC5750268.
3: Guja C, Dănciulescu Miulescu R. Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists? Ann Transl Med. 2017 Dec;5(23):475. doi: 10.21037/atm.2017.10.09. PubMed PMID: 29285508; PubMed Central PMCID: PMC5733318.
4: Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2017 Dec 15. pii: dc170417. doi: 10.2337/dc17-0417. [Epub ahead of print] PubMed PMID: 29246950.
5: Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment. Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13186. [Epub ahead of print] PubMed PMID: 29205786.
6: Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, Helmark IC, Wijayasinghe N, Larsen M. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13172. [Epub ahead of print] PubMed PMID: 29178519.
7: Hawkes N. Sixty seconds on . . . semaglutide. BMJ. 2017 Nov 1;359:j5010. doi: 10.1136/bmj.j5010. PubMed PMID: 29092887.
8: Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 Oct 17;318(15):1460-1470. doi: 10.1001/jama.2017.14752. PubMed PMID: 29049653.
9: Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2017 Sep 23. doi: 10.1111/dom.13120. [Epub ahead of print] PubMed PMID: 28941314.
10: Anderson TW, Granhall C, Réthy Á, Søndergaard FL, Thomsen M. Erratum to: Abstracts of the 53rd Annual Meeting of the EASD, Lisbon 2017. Abstract 788: 'Pharmacokinetics and tolerability of oral semaglutide in subjects with renal impairment'. Diabetologia. 2017 Sep;60(Suppl 1):609. doi: 10.1007/s00125-017-4413-1. PubMed PMID: 28835978.
11: Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13082. [Epub ahead of print] PubMed PMID: 28786547.
12: Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2017 Sep;26(9):1083-1089. doi: 10.1080/13543784.2017.1360274. Epub 2017 Aug 2. Review. PubMed PMID: 28741970.
13: Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 Aug;60(8):1390-1399. doi: 10.1007/s00125-017-4289-0. Epub 2017 May 19. PubMed PMID: 28526920; PubMed Central PMCID: PMC5491562.
14: Sorli C. Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply. Lancet Diabetes Endocrinol. 2017 May;5(5):330. doi: 10.1016/S2213-8587(17)30110-9. PubMed PMID: 28434491.
15: Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol. 2017 May;5(5):329-330. doi: 10.1016/S2213-8587(17)30109-2. PubMed PMID: 28434490.
16: Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3. PubMed PMID: 28385659.
17: Madsbad S, Holst JJ. Glycaemic control and weight loss with semaglutide in type 2 diabetes. Lancet Diabetes Endocrinol. 2017 May;5(5):315-317. doi: 10.1016/S2213-8587(17)30094-3. Epub 2017 Apr 3. PubMed PMID: 28385658.
18: Hausner H, Derving Karsbøl J, Holst AG, Jacobsen JB, Wagner FD, Golor G, Anderson TW. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017 Nov;56(11):1391-1401. doi: 10.1007/s40262-017-0532-6. PubMed PMID: 28349387; PubMed Central PMCID: PMC5648738.
19: Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. Clin Pharmacokinet. 2017 Nov;56(11):1381-1390. doi: 10.1007/s40262-017-0528-2. PubMed PMID: 28349386; PubMed Central PMCID: PMC5648736.
20: Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017 May;5(5):355-366. doi: 10.1016/S2213-8587(17)30085-2. Epub 2017 Mar 23. PubMed PMID: 28344112.
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
